BioLineRx (BLRX) Stock Price, News & Analysis

Company Overview

BioLineRx (NASDAQ: BLRX) is a clinical-stage biopharmaceutical company that discovers and develops novel small-molecule therapies to address unmet medical needs. The company focuses on identifying promising drug candidates through licensing and collaboration agreements with academic institutions and biotech innovators, then advancing these candidates through preclinical and clinical development stages. BioLineRx’s pipeline spans oncology, immunology and inflammatory diseases, central nervous system disorders and pain management.

Among its clinical programs, BioLineRx is advancing targeted cancer therapies designed to improve outcomes for patients with difficult-to-treat tumors. In immunology and inflammatory diseases, the company is developing novel agents that modulate key biological pathways to reduce disease activity with minimal side effects. BioLineRx also explores treatments for neuropathic pain and other central nervous system conditions, seeking to offer new therapeutic options where few effective treatments exist.

Headquartered in Modi’in, Israel, BioLineRx maintains strategic partnerships and licensing arrangements across North America, Europe and Asia to support its global development efforts. By leveraging a business model that combines in-licensing, co-development and out-licensing of assets, the company aims to maximize the value of its pipeline while managing development risk. BioLineRx collaborates with contract research organizations and clinical centers worldwide to conduct multi-site trials and accelerate the advancement of its drug candidates.

Key Stats

• Today's Range: $3.23 to $3.45
• 50-Day Range: $2.23 to $3.78
• 52-Week Range: $2.15 to $5.06
• Volume: 74,144 shs
• Average Volume: 33,621 shs
• Market Capitalization: $14.25 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

BioLineRx Stock Analysis - MarketRank™

BioLineRx scored higher than 6% of companies evaluated by MarketBeat, and ranked 831st out of 850 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

BioLineRx has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

BioLineRx has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of BioLineRx is -1.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BioLineRx is -1.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

BioLineRx has a P/B Ratio of 0.61. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.86% of the float of BioLineRx has been sold short.

Short Interest Ratio / Days to Cover

BioLineRx has a short interest ratio ("days to cover") of 0.81, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BioLineRx has recently increased by 19.45%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BioLineRx does not currently pay a dividend.

Dividend Growth

BioLineRx does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for BioLineRx this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for BLRX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

1 people have added BioLineRx to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, BioLineRx insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.10% of the stock of BioLineRx is held by insiders.

Percentage Held by Institutions

1.56% of the stock of BioLineRx is held by institutions.

Company Calendar

• Last Earnings: 5/27/2026
• Today: 6/23/2026
• Next Earnings (Estimated): 8/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BLRX
• CIK: 1498403
• Web: www.biolinerx.com
• Phone: (728) 642-9100
• Fax: 972-8642-9101
• Employees: 40
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($1.92)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$1.17 million
• Net Margins: -563.70%
• Pretax Margin: -694.79%
• Return on Equity: -37.73%
• Return on Assets: -19.42%

Debt

• Debt-to-Equity Ratio: 0.16
• Current Ratio: 1.58
• Quick Ratio: 1.43

Sales & Book Value

• Annual Sales: $1.18 million
• Price / Sales: 12.07
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.36 per share
• Price / Book: 0.61

Miscellaneous

• Outstanding Shares: 4,370,000
• Free Float: 4,320,000
• Market Cap: $14.25 million
• Optionable: Optionable
• Beta: 1.53